Close mobile menu×
Close mobile menu

Magdalena E. Sobieszczyk, MD, MPH

Board Certifications: 
Infectious Disease
Not Accepting New Patients
Profile Hero

Appointments

myColumbiaDoctors

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

Board Certifications

  • Infectious Disease

Clinical Expertise

  • HIV Medicine
  • HIV/AIDS
  • Infectious Disease
  • HIV (Human Immunodeficiency Virus Infection)

Specialties

Education & Training

  • Columbia University College of Physicians and Surgeons
  • Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Fellowship: NewYork-Presbyterian Hospital/Columbia University Medical Center

About Magdalena Sobieszczyk

Academic Titles

  • Associate Professor of Medicine at CUMC

Administrative Positions

  • Associate Fellowship Program Director

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Gender

  • Female

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Essential Plan
  • Medicaid Managed Care
  • Medicare Managed Care

Amida Care

  • Special Needs Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • HMO
  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • Blue Priority
  • EPO
  • HMO
  • Medicare (Mediblue)
  • NYP Employee Plan
  • Pathway (Exchange)
  • POS
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Medicare

  • Traditional Medicare (NY)

Multiplan

  • Multiplan

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • EPO
  • Essential Plan
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
180 Fort Washington Avenue
Suite 2-242
New York, New York 10032
Phone:
(212) 305-8039
Fax:
(212) 305-1754
Primary

Research

Dr. Magdalena Sobieszczyk is the PI of the NIH-funded Columbia HVTN and ACTG Clinical Research Site.  Her research focuses on developing, testing, and implementation of biomedical strategies to prevent HIV infection, specifically preventive HIV vaccines and pre-exposure prophylaxis (PrEP).  Particular interests include assessing combination biomedical prevention strategies such as vaccines together with oral and topical PrEP; and evaluating host factors influencing immunologic and virologic course of HIV disease and response to vaccination in study participants. She has been involved in the development and implementation of several international and national HIV prevention protocols and is the co-chair of phase 2b HIV vaccine protocol to determine the safety and efficacy of the DNA prime-Ad5 boost vaccine regimen in individuals at risk of HIV infection (HVTN 505).

Her research with HIV infected individuals includes investigating HIV testing and linkage to care in the predominantly Latino communities of northern Manhattan. This also includes describing the prevalence of metabolic and renal abnormalities in this population and in South African cohorts.

Dr. Sobieszczyk is also a co-investigator of the Centre for the AIDS Program of Research in South Africa (CAPRISA) project entitled “Viral Setpoint and Clinical Progression in HIV-1 Subtype C Infection: The Role of Immunological and Viral Factors During Acute and Early Infection” (Salim Abdool Karim, PI). 

Research Interests

  • HIV prevention strategies, specifically clinical trials of preventive HIV vaccines

Grants

CLINICAL AND TRANSLATIONAL SCIENCE AWARD (Federal Gov)

Jul 1 2016 - May 31 2021

COLUMBIA PARTNERSHIP FOR PREVENTION AND CONTROL OF HIV/AIDS CLINICAL TRIALS UNIT (COLUMBIA PARTNERSHIP CTU) (Federal Gov)

Dec 1 2013 - Nov 30 2020

A PHASE IIA STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND ACCEPTABILITY OF LONG ACTING INJECTIONS OF THE HIV INTEGRASE INHIBITOR, GSK1265744, IN HIV UNINFECTED MEN (ECLAIR) (P&S Industry Clinical Trial)

Jun 9 2014 - Jun 9 2019

HVTN CORRELATES PHASE 1 FUNDING (PF) (HVTN 108 AND HVTN 120) (Federal Gov)

Dec 1 2017 - Nov 30 2018

HVTN CORRELATES PHASE 1 FUNDING (PF) (HVTN 108 AND HVTN 120) (Private)

Dec 1 2017 - Nov 30 2018

HPTN 083 PROTOCOL FUNDING - DEVELOPMENT COST (Federal Gov)

May 1 2016 - Nov 30 2018

HPTN 081/085 PROTOCOL FUNDING - IMPLEMENTATION - CENTRALIZED LABORATORY AND OTHER OPERATIONAL SUPPORT (Federal Gov)

May 1 2016 - Nov 30 2018

A PILOT STUDY EVALUATING THE USE OF NOVEL SELF-ADMINISTERED DRIED BLOOD SPOT DEVICE - HEMASPOT - TO MONITOR PREP USE AMONG MEN WHO HAVE SEX WITH MEN (Federal Gov)

Jul 1 2016 - Jun 30 2017

REPRIEVE A5332 KIDNEY FUNCTION SUB STUDY (Federal Gov)

Jul 1 2016 - Jun 30 2017

PITAVASTATIN TO REDUCE PHYSICAL FUNCTION IMPAIRMENT AND FRAILTY IN HIV (PREPARE) (Federal Gov)

Aug 1 2016 - May 31 2017

HVTN 703/ HPTN 081 SITE READINESS (Federal Gov)

Jul 1 2015 - Nov 30 2016

REPRIEVE A5332 AND A5333S (Federal Gov)

Aug 8 2014 - Apr 30 2016

HVTN RESEARCH AND MENTORSHIP PROGRAM (RAMP) (Federal Gov)

Jun 1 2015 - Nov 30 2015

HVTN SCIENTIFIC LEADERSHIP (SOBIESZCAYK) (Federal Gov)

Dec 1 2014 - Nov 30 2015

HVTN PROTOCOL FUNDING (Federal Gov)

Jun 1 2014 - Feb 28 2015

AIDS CLINICAL TRIALS GROUP PROTOCOL FUNDS (Federal Gov)

Jun 1 2014 - Nov 30 2014

DORIS DUKE CLINICAL RESEARCH FELLOWSHIP PROGRAM (Private)

Jan 1 2011 - Jun 30 2014

HVTN CLINICIAN (Federal Gov)

Jul 1 2005 - Jun 30 2014

NEW HIV DIAGNOSES, LINKAGE TO CARE, AND TREATMENT OUTCOMES AMONG LATINO AND AFRICAN-AMERICAN OLDER ADULTS IN NYC (Private)

Jun 1 2012 - Dec 31 2013

HVTN 505CORE LEADERSHIP ROLE (Federal Gov)

Jun 1 2009 - Dec 31 2013

HVTN SCIENTIFIC LEADERSHIP (Federal Gov)

Jun 1 2009 - Dec 31 2013

ENHANCING, TRAINING, RESEARCH CAPACITY AND EXPERTISE IN HIV CARE-ENTREE MEDICAL EDUCATION PARTNERSHIP INITIATIVE (Federal Gov)

Sep 27 2010 - Aug 31 2013

HIV VACCINE TRIALS UNIT - HVTN 505 (Federal Gov)

Jun 1 2009 - Aug 31 2013

KNOWLEDGE, ATTITUDES, AND WILLINGNESS OF NYC PROVIDERS OF PR ESCIBE SYSTEMIC ANTIRETROVIRAL CHEMOPROP (Private)

Sep 1 2011 - May 31 2013

Selected Publications

Sobieszczyk ME, Werner L, Mlisana K, Naicker N, Feinstein A, Gray CM, Masson L, Passmore JS, Williamson C, Karim QA, Abdool Karim SS, Garret NJ. Metabolic syndrome after HIV acquisition in South African women. J Acquir Immune Defic Syndr. 2016 Jul 6. [Epub ahead of print]

Williams WB, Liao HX, Moody MA, Kepler TB, Alam SM, Gao F, Wiehe K, Trama AM, Jones K, Zhang R, Song H, Marshall DJ, Whitesides JF, Sawatzki K, Hua A, Liu P, Tay MZ, Seaton KE, Shen X, Foulger A, Lloyd KE, Parks R, Pollara J, Ferrari G, Yu JS, Vandergrift N, Montefiori DC, Sobieszczyk ME, Hammer S, Karuna S, Gilbert P, Grove D, Grunenberg N, McElrath MJ, Mascola JR, Koup RA, Corey L, Nabel GJ, Morgan C, Churchyard G, Maenza J, Keefer M, Graham BS, Baden LR, Tomaras GD, Haynes BF. HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. Science. 2015 Aug 14;349(6249):aab1253. Epub 2015 Jul 30.

Dawson L, Garner S, Anude C, Ndebele P, Karuna S, Holt R, Broder G, Handibode J, Hammer S, Sobieszczyk ME. Testing the waters: ethical considerations for including PrEP in a phase IIb HIV vaccine efficacy trial. Clinical trials. Apr 7, 2015.

Ellman TM, Hawkins K, Benitez J, Negron R, Chang S, Palmer S, Robertson V, Chiasson MA, Sobieszczyk ME. Representation of Latino and Black Men and Transgender women Screening and Enrolling into Preventive HIV Vaccine Trials in New York City. Vaccine. 2015;33(48):6809-15. PMID:26458799

Tang E., Sobieszczyk ME., Shu E., Gonzalez P., Sanchez J., Lama J. Provider Attitudes toward Oral Pre-Exposure Prophylaxis for HIV Prevention among High-Risk MSM in Lima, Peru. AIDS Research and Human Retroviruses 30(5):416-24.2014

Ellman TM, Sexton ME, Warshafsky D, Sobieszczyk ME, Morrison E.  A Forgotten Population: Older Adults Newly-Diagnosed with HIV. AIDS Patient Care and STDs. Volume 28, Number 10, 2014

Hammer S.M., Sobieszczyk ME, Janes H. et al. Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine. New England J of Medicine, 2013 10.1056/NEJMoa1310566.

Tieu HV, Rolland M, Hammer SM, Sobieszczyk ME. Translational Research Insights from Completed HIV Vaccine Efficacy Trials. Journal of AIDS 2013; (63) Supplement 2, July 1

Mlisana K, Sobieszczyk ME, Loggerenberg F, Feinstein A, Werner L, Feinstein A, Williamson C, Loggerenberg F, Karim S. Challenges of diagnosing acute HIV-1 subtype C infection in African women: Performance of a clinical algorithm and the need for point-of-care nucleic acid based testing. PLoS ONE 2013; 8(4): e62928.

Janes H, Gilbert P, Buchbinder S, Kublin J, Sobieszczyk ME, and Hammer SM. In Pursuit of an HIV Vaccine: Designing Efficacy Trials in the Context of Partially Effective Nonvaccine Prevention Modalities. AIDS Research and Human Retroviruses 2013. ahead of print. doi:10.1089/aid.2012.0385

Sobieszczyk ME, Lingappa J, McElrath JM. Host genetic polymorphisms associated with innate immune factors and HIV-1. Curr Opinion HIV/AIDS 2011; 6 (5): 427-434